GLP-1 Pipeline Update: August 2025 Quarterly view of the GLP-1 pipeline and anticipated indications Editorial team Maryam Tabatabai, PharmD Editor-In-Chief Associate Vice President, Clinical Information Carole Kerzic, RPh Executive Editor Drug Information Pharmacist Principal Nicole Kjesbo, PharmD, BCPS Executive Editor Clinical Program Development Director Senior, Pipeline DISCLAIMER The drug pipeline is fluid
Inositol: Contributes to converting food into energy, enhancing metabolic rate and facilitating fat loss
For women on GLP-1 therapy who are losing weight at a meaningful pace, bone health is worth monitoring, particularly in perimenopausal and postmenopausal women where estrogen-related bone protection is already diminishing
Studies demonstrate that semaglutide primarily reduces fat mass while preserving muscle tissue, with approximately 65% of weight loss coming from fat reduction.[6] Recent clinical trials show that combining semaglutide with resistance training and adequate protein intake can preserve 50-80% of lean mass that might otherwise be lost during weight reduction